PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for ...
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide ...
Hosted by Biogen, the one-day summit brings together patients, physicians, partners and supporters to create a strong, cohesive, empathetic and knowledgeable nano-rare community. n-Lorem has made ...
Please provide your email address to receive an email when new articles are posted on . Few patients with cystic fibrosis have a copy of the 3849+10kb C-to-T splicing mutation. Research is planned to ...
Drugmakers can now call on a host of RNA therapeutic modalities, but small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs still garner the highest upfront payments. Oligo therapies ...
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide ...
-- Collaboration provides GondolaBio access to n-Lorem's AI-informed, world-class ASO capabilities to discover novel ASO medicines for patients in need -- GondolaBio is a clinical-stage biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback